mTOR inhibitors in pediatric liver transplant recipients-Reference-Cited by-同舟云学术

mTOR inhibitors in pediatric liver transplant recipients

Published:2019-08 Issue:4 Volume:43 Page:403-409
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Dumortier Jérôme,Couchonnal Eduardo,Lacaille Florence,Rivet Christine,Debray Dominique,Boillot Olivier,Lachaux Alain,Ackermann Oanez,Gonzales Emmanuel,Wildhaber Barbara E.,Jacquemin Emmanuel,McLin Valérie

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference20 articles.

1. Liver cirrhosis;Schuppan;Lancet,2008

2. Immunosuppressive therapy in liver transplantation;Conti;J Hepatol,2003

3. Use of everolimus in liver transplantation: The French experience;Dumortier;Transplant Rev (Orlando),2016

4. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial;De Simone;Liver Transpl,2009

5. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function;Masetti;Am J Transplant,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review;Pediatric Drugs;2024-09-09

2. Sirolimus to treat chronic and steroid‐resistant allograft rejection‐related fibrosis in pediatric liver transplantation;Journal of Pediatric Gastroenterology and Nutrition;2024-07-08

3. LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway;Scientific Reports;2023-05-09

4. LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway;2022-10-03

5. Everolimus is Safe as a Second-/Third-Line Therapy in Pediatric Autoimmune Hepatitis;JPGN Reports;2022-08